Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
report source : Www.vynetherapeutics.com save search
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
Published: 2023-03-09 (Crawled : 23:00) - vynetherapeutics.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: -3.33%
H: 6.9%
C: 3.45%
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -1.31%
H: 1.32%
C: -0.66%
therapeutics financial update results
VYNE Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-10 (Crawled : 22:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 8.28%
H: 0.0%
C: -6.26%
therapeutics financial update results
VYNE Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Published: 2022-05-12 (Crawled : 22:00) - vynetherapeutics.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: 0.0%
H: 5.79%
C: 4.27%
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -2.45%
H: 8.11%
C: 0.32%
therapeutics results
VYNE Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an In Vivo Model of Rheumatoid Arthritis
Published: 2022-03-30 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.81%
H: 10.86%
C: 7.89%
vyn201 preclinical positive injection pre-clinical
VYNE Therapeutics Reports Year-End 2021 Financial Results and Provides Corporate Update
Published: 2022-03-17 (Crawled : 12:30) - vynetherapeutics.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: 1.76%
H: 4.32%
C: -2.81%
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 0.0%
H: 8.8%
C: 6.09%
financial results therapeutics report results
VYNE Reports Positive Preclinical Data for Lead BET Inhibitor, VYN201, in Human Skin Model of Vitiligo
Published: 2022-03-07 (Crawled : 12:30) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -1.09%
H: 4.04%
C: 0.12%
vyn201 pos skin preclinical report positive pre-clinical
VYNE Therapeutics to Report Third Quarter 2021 Financial Results on November 10, 2021
Published: 2021-10-28 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: 0.0%
H: 2.38%
C: 1.59%
financial results results
VYNE Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Published: 2021-05-06 (Crawled : 12:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -7.08%
H: 1.43%
C: -15.24%
financial results results
VYNE Therapeutics to Report First Quarter 2021 Financial Results on May 6, 2021
Published: 2021-04-28 (Crawled : 13:00) - vynetherapeutics.com
VYNE | $2.65 14.22% 12.45% 380K
|
Health Technology
|
| O: -0.19%
H: 1.73%
C: 0.0%
financial results results
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.